{"id":12269,"date":"2019-12-02T20:51:00","date_gmt":"2019-12-02T20:51:00","guid":{"rendered":"http:\/\/eurojournalists.com\/?guid=094ee13dc035113658cc628295463218"},"modified":"2019-12-02T20:51:00","modified_gmt":"2019-12-02T20:51:00","slug":"biogens-stock-could-fall-10-on-new-alzheimers-drug-data-this-week-top-analyst-says-cnbc","status":"publish","type":"post","link":"https:\/\/eurojournalists.com\/?p=12269","title":{"rendered":"Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says – CNBC"},"content":{"rendered":"
    \n
  1. Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says<\/a>  CNBC<\/font><\/li>\n
  2. Analyst: Biogen’s aducanumab is not getting approved absent a deus ex machina<\/a>  FierceBiotech<\/font><\/li>\n
  3. Biogen Stock: Why Alzheimer’s Treatment Data Could Rock The Biogen Company<\/a>  Investor’s Business Daily<\/font><\/li>\n
  4. Top Biogen scientist explains why he’s confident in aducanumab<\/a>  STAT<\/font><\/li>\n
  5. Biogen\u2019s Alzheimer\u2019s Drug Won\u2019t Get Approved, Analyst Says<\/a>  Barron’s<\/font><\/li>\n
  6. View full coverage on Google News<\/a><\/strong><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says  CNBCAnalyst: Biogen’s aducanumab is not getting approved absent a deus ex machina  FierceBiotechBiogen Stock: Why Alzheimer’s Treatment Data Cou…<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-12269","post","type-post","status-publish","format-standard","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/eurojournalists.com\/index.php?rest_route=\/wp\/v2\/posts\/12269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/eurojournalists.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eurojournalists.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eurojournalists.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/eurojournalists.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=12269"}],"version-history":[{"count":1,"href":"https:\/\/eurojournalists.com\/index.php?rest_route=\/wp\/v2\/posts\/12269\/revisions"}],"predecessor-version":[{"id":12270,"href":"https:\/\/eurojournalists.com\/index.php?rest_route=\/wp\/v2\/posts\/12269\/revisions\/12270"}],"wp:attachment":[{"href":"https:\/\/eurojournalists.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=12269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eurojournalists.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=12269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eurojournalists.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=12269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}